Summary:
A gluten-free diet (GFD) involves avoiding foods containing gluten, such as wheat, barley, and rye. It is the primary treatment for celiac disease, and the only effective therapy, helping to relieve symptoms, promote intestinal healing, and prevent complications. More recently, use of a GFD has expanded among people without celiac disease who believe it may provide general health benefits. Despite this trend, there are no formal guidelines supporting its use in non-celiac populations, and evidence for benefits in autoimmune-related diseases remains limited. This study is a Mendelian randomisation study that used genetic variants to explore whether a gluten-free diet may have an effect on autoimmune-related diseases, and analysed data from more than 500,000 people in the UK Biobank. It used genetic markers linked to following a gluten-free diet to explore whether there was any relationship with disease outcomes. The results showed that people with genetic traits associated with a gluten-free diet had a lower risk of developing rheumatoid arthritis (RA), meaning people were grouped based on genetic markers that are linked to behaviours or characteristics that correlate with eating gluten-free, were less likely to develop RA. Further analysis suggested this effect might partly be explained by small changes in certain immune cells, including specific types of monocytes and B cells. Overall, the findings suggest that a gluten-free dietary pattern may be linked with a reduced risk of RA, possibly through effects on the immune system. However, more research is needed to confirm this and understand exactly how it works.
Abstract:
While the gluten-free diet (GFD) is primarily used to treat celiac disease (CD), recent research suggests it may also offer benefits for autoimmune-related diseases (ARDs), though findings remain inconsistent. This study aimed to investigate the potential protective effect of a GFD against ARDs by Mendelian Randomization (MR) analysis. Utilizing data from over 500,000 samples from the UK Biobank and other publicly available genome-wide association studies (GWAS), MR analysis revealed a significant negative causal relationship between GFD and the risk of developing rheumatoid arthritis (RA) (OR = 0.782, 95% CI = [0.727-0.841], p < 0.001). Mediation analysis identified immune cells such as CD14+ CD16+ monocyte absolute count (mediating 2.441% of the effect), CD14+ CD16+ monocyte percentage (2.346%), and CD20 on IgD+ CD38^dim B cells (3.119%) as potential mediators in the protective effect of GFD on RA. These findings suggest that GFD may help reduce RA risk by modulating specific immune cell populations. However, further research is necessary to clarify the exact mechanisms underlying these associations.
Article Publication Date: 01/01/2025
DOI: 10.7150/ijms.104928
